Effektiviteten af SpaceOAR Vue-systemet hos personer med prostatakræft, der behandles med stereootaktisk kropsstrålebehandling (SABRE)
To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This study is designed to evaluate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in participants undergoing Stereotactic Body Radiotherapy (SBRT) for the treatment of prostate cancer.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Waratah, New South Wales, Australien, 2298
- Calvary Mater Newcastle
-
-
Queensland
-
Woolloongabba, Queensland, Australien, 4102
- Princess Alexandra Hospital - ROPAIR
-
-
Western Australia
-
Nedlands, Western Australia, Australien, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
-
Belfast, Det Forenede Kongerige, BT9 7AB
- Belfast City Hospital
-
Bristol, Det Forenede Kongerige, BS2 8ED
- Bristol Haematology and Oncology Centre
-
London, Det Forenede Kongerige, SW3 6JJ
- Royal Marsden Hospital
-
Norwich, Det Forenede Kongerige, NR4 7UY
- Norfolk and Norwich University Hospital NHS Trust
-
Plymouth, Det Forenede Kongerige, PL6 8DH
- Derriford General Hospital
-
-
Surrey
-
Guildford, Surrey, Det Forenede Kongerige, GU27XX
- Royal Surrey County Hospital NHS Foundation Trust
-
-
Wales
-
Cardiff, Wales, Det Forenede Kongerige, CF14 2TL
- Velindre Cancer Centre
-
-
-
-
Florida
-
Fort Myers, Florida, Forenede Stater, 33908
- GenesisCare USA
-
Tampa, Florida, Forenede Stater, 33609
- Florida Urology Partners, LLC
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Kansas University Medical Center
-
-
Michigan
-
Troy, Michigan, Forenede Stater, 48098
- GenesisCare USA
-
-
New Jersey
-
Bloomfield, New Jersey, Forenede Stater, 07003
- New Jersey Urology, a Summit Health Company
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- University of Pittsburgh Medical Center
-
-
South Carolina
-
Myrtle Beach, South Carolina, Forenede Stater, 29572
- Dr. John Sylvester
-
-
-
-
-
Levallois-Perret, Frankrig, 92300
- Institut de Radiothérapie & Radiochirurgie HARTMANN
-
-
Cedex
-
Villejuif, Cedex, Frankrig, 94805
- Institut Gustave Roussy
-
-
-
-
-
Cork, Irland, T12 DV56
- Bon Secours Radiotherapy Cork
-
-
-
-
-
Parma, Italien, 43126
- Azienda Ospedaliero Universitaria di Parma
-
Rome, Italien
- Policlinico Universitario Agostino Gemelli
-
Verona, Italien, 37024
- IRCCS Ospedale Sacro Cuore Don Calabria
-
-
-
-
-
Basel, Schweiz, CH-4031
- University Hospital Basel
-
Bern, Schweiz, 3010
- Inselspital - University Hospital Bern
-
-
-
-
-
Barakaldo, Spanien, 48903
- Hospital Universitario Cruces
-
Madrid, Spanien, 28002
- GenesisCare, Hospital San Francisco de Asis
-
Madrid, Spanien
- Hospital Universitario Ramón y Cajal
-
-
-
-
-
Bonn, Tyskland, D-53129
- MEDICLIN Robert Janker Klinik
-
Nuremberg, Tyskland, 90419
- Klinikum Nurnberg Nord
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years old.
- Subjects must have pathologically confirmed (by routine hematoxylin and eosin (H&E) staining) invasive adenocarcinoma of the prostate and been planning to undergo SBRT.
- Subjects must have intermediate risk prostate cancer as defined by the presence of one or more of the following:
- Clinical Stage T2b - T2c (AJCC 6th edition) tumor
- Gleason Score 7 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
- Demonstrated blood PSA levels 10-20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
- Subject or authorized representative was informed of the nature of the study and provided written informed consent, approved by the appropriate Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site.
Exclusion Criteria:
- Prostate >80 cc documented within 9 months preceding Enrollment (randomization)
- Clinical stage T3 or T4 (AJCC 6th edition) tumor
- Blood PSA level >20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
- Gleason Score ≥ 8 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
- Subjects who had MRI evidence of gross posterior extracapsular extension (ECE) of the prostate cancer. (Note: MRI should be from within 9 months preceding Enrollment (randomization). If MRI is contraindicated, a digital rectal exam may be performed to confirm the absence of gross posterior ECE)
- Subjects who had metastatic disease, other ongoing cancers which were treated during the study or subjects for whom pelvic lymph node radiotherapy was planned.
- Subjects with any prior invasive malignancy (except non-melanomatous skin cancer) unless the subject had been disease free for a minimum of 3 years.
- History of prostatectomy, transurethral prostate surgery (e.g. TUNA, TUMT, TURP) if performed within 1 year prior to screening, other local prostate cancer therapy (e.g., cryotherapy or brachytherapy) or previous pelvic irradiation at any time prior to screening.
- History of prior pelvic surgery requiring low anterior or abdominoperineal resections or rectal surgery.
- History of or active inflammatory bowel disease (IBD) such as Crohn's disease or ulcerative colitis.
- History of or current perirectal disease that may interfere with interpretation of study outcomes including anal or perianal diseases such as fistula.
- Bleeding hemorrhoids requiring medical intervention within the prior three months.
- Diagnosed active bleeding disorder or a clinically significant coagulopathy. Note: Patients on anticoagulants may be included if the anticoagulant medication can be discontinued for index procedure.
- Active inflammatory or infectious process involving the perineum, gastrointestinal (GI) or urinary tract based on positive diagnosis or suspected diagnosis in the presence of fever >38⁰ C, WBC > 12,000/uL.
- Compromised immune system or prior diagnoses for human immunodeficiency virus (HIV) (with a detectable viral load within the last 6 months)/acquired immunodeficiency syndrome (AIDS) or autoimmune disease.
- If a subject was enrolled in another investigational drug or device trial that had not completed the primary endpoint or that clinically interfered with this study.
- Unable to comply with the study requirements or follow-up schedule.
- Any condition the Investigator believed would interfere with the intent of the study or would make participation not in the best interest of the patient.
- Known iodine sensitivity or allergy
- Known polyethylene glycol (PEG) sensitivity or allergy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Ingen indgriben: No-Spacer Control
Subjects will receive radiotherapy without the use of the SpaceOAR Vue. |
|
|
Eksperimentel: SpaceOAR Vue
Subjects will receive radiotherapy following injection of the SpaceOAR Vue hydrogel. |
The SpaceOAR Vue System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the SpaceOAR Vue System to reduce the radiation dose delivered to the anterior rectum. The SpaceOAR Vue System is composed of biodegradable material, maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Late Gastrointestinal (GI) Toxicity
Tidsramme: 3 to 24 months post-SBRT initiation
|
Proportion of subjects experiencing late GI toxicity after SBRT treatment with or without placement of the SpaceOAR Vue System hydrogel. Late GI toxicity is defined as the occurrence of a Grade 2 or greater GI adverse event (NCI CTCAE v4) between 3- and 24-months post-SBRT initiation |
3 to 24 months post-SBRT initiation
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
EPIC-26 bowel score
Tidsramme: 24 months post-SBRT initiation
|
Proportion of subjects experiencing a decrease in EPIC-26 bowel score greater than or equal to the minimal important difference (MID) in EPIC-26 bowel score from baseline to 24 months post-SBRT initiation. |
24 months post-SBRT initiation
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Suneil Jain, MB, BCh, PhD, Queen's University, Belfast
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- U0702
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .